Related Experiment Videos
The SH2 domain: versatile signaling module and pharmaceutical target
Kazuya Machida1, Bruce J Mayer
1Raymond and Beverly Sackler Laboratory of Genetics and Molecular Medicine, Department of Genetics and Developmental Biology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3301, USA. machida@neuron.uchc.edu
Biochimica Et Biophysica Acta
|February 1, 2005
Summary
The Src homology 2 (SH2) domain is crucial for protein tyrosine kinase (PTK) signaling. Researchers are developing SH2 domain inhibitors to treat diseases by modulating PTK pathways.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Signaling
Background:
- The Src homology 2 (SH2) domain is a prevalent phosphotyrosine-binding module.
- SH2 domains are structurally conserved across diverse proteins, playing vital roles in cellular signaling pathways.
- These domains exhibit versatility and flexibility in ligand binding, influencing various cellular functions.
Purpose of the Study:
- To illustrate the functional versatility of SH2 domains using examples from SAP, Cbl, and SOCS protein families.
- To highlight advancements in developing SH2 domain inhibitors for therapeutic applications.
- To explore structure-based strategies for overcoming challenges in SH2 ligand design.
Main Methods:
- Analysis of SH2 domain function in SAP, Cbl, and SOCS protein families.
- Review of current progress in SH2 domain inhibitor development.
- Examination of structure-based drug design strategies for SH2 ligands.
Main Results:
- SH2 domains in SAP, Cbl, and SOCS families are critical for immune, PTK termination, and cytokine responses.
- Inhibitors targeting Grb2 and Src SH2 domains show potential for Ras pathway and bone resorption modulation.
- Structure-based design has yielded high-affinity SH2 ligands with cellular activity, overcoming previous limitations.
Conclusions:
- SH2 domains are versatile regulators of protein tyrosine kinase signaling.
- SH2 domain inhibitors represent a promising therapeutic strategy for various human diseases.
- Advances in drug design offer new insights into SH2 domain molecular recognition and therapeutic potential.